{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:34:40Z","timestamp":1786977280700,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effect of secukinumab (interleukin\u201017A inhibitor) on patient\u2010reported outcomes in patients with active ankylosing spondylitis (AS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase III study, 371 patients were randomized (1:1:1) to receive intravenous (IV) secukinumab 10 mg\/kg at baseline and weeks 2 and 4 followed by subcutaneous (SC) secukinumab 150 mg every 4 weeks (IV\u2192150 mg group), or SC secukinumab 75 mg every 4 weeks (IV\u219275 mg group), or placebo. Patient\u2010reported outcomes included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI criteria for 50% improvement (BASDAI 50), Short Form 36 (SF\u201036) physical component summary (PCS) score and mental component summary (MCS) score, Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, Bath Ankylosing Spondylitis Functional Index (BASFI), EuroQol 5\u2010domain (EQ\u20105D) questionnaire, Functional Assessment of Chronic Illness Therapy\u2013Fatigue (FACIT\u2010F), and Work Productivity and Activity Impairment\u2013General Health questionnaire (WPAI\u2010GH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 16, secukinumab IV\u2192150 mg or IV\u219275 mg was associated with statistically and clinically significant improvements from baseline versus placebo in the BASDAI (\u22122.3 for both regimens versus \u22120.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively), SF\u201036 PCS (5.6 for both regimens versus 1.0;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt; 0.001, respectively), and ASQoL (\u22123.6 for both regimens versus \u22121.0;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). Clinically significant improvements in the SF\u201036 MCS, BASFI, EQ\u20105D, and BASDAI 50 were observed with both secukinumab groups versus placebo at week 16; improvements were also observed in the FACIT\u2010F and WPAI\u2010GH. All improvements were sustained through week 52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that secukinumab provides significant and sustained improvements in patient\u2010reported disease activity and health\u2010related quality of life, and reduces functional impairment, fatigue, and impact of disease on work productivity in patients with active AS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.39805","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T11:26:20Z","timestamp":1467890780000},"page":"2901-2910","source":"Crossref","is-referenced-by-count":76,"title":["Effect of Secukinumab on Patient\u2010Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)"],"prefix":"10.1002","volume":"68","author":[{"given":"Atul A.","family":"Deodhar","sequence":"first","affiliation":[{"name":"Oregon Health &amp; Science University Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[{"name":"H\u00f4pital Cochin, Paris Descartes University Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L.","family":"Baeten","sequence":"additional","affiliation":[{"name":"University of Amsterdam Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cheng\u2010Chung Wei","sequence":"additional","affiliation":[{"name":"Chung Shan Medical University Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Geusens","sequence":"additional","affiliation":[{"name":"Maastricht University Hospital Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Readie","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno B.","family":"Richards","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2661-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.007"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.44.6.359"},{"key":"e_1_2_8_5_1","first-page":"496","article-title":"Incidence and prevalence of ankylosing spondylitis in Finland","volume":"24","author":"Kaipiainen\u2010Seppanen O","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh133"},{"key":"e_1_2_8_7_1","first-page":"2245","article-title":"Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study","volume":"30","author":"Dai SM","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_8_1","first-page":"554","article-title":"Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society","volume":"28","author":"Hukuda S","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.604313"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328346f7fb"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023176"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204963"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002653"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33396"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1647-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_24_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_25_1","volume-title":"SF\u201036 health survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"e_1_2_8_27_1","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"e_1_2_8_30_1","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000063619.37065.e2"},{"key":"e_1_2_8_32_1","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen A","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1928-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20233"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.06.002"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513488501"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-9-36"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201915"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.1033"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39805","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:56:20Z","timestamp":1759935380000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1002\/art.39805"],"URL":"https:\/\/doi.org\/10.1002\/art.39805","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}